To evaluate the efficacy of different botulinum toxin A injection patterns in treating benign essential blepharospasm and to compare their influence on condition of eye surface .
The authors performed a prospective double-blinded randomised clinical trial of 60 patients with an established diagnosis of benign essential blepharospasm from February 2013 to December 2015. Patients received a full injection pattern of 5 sites on one eye and a medial lower eyelid waived injection pattern of 4 sites on the other eye randomly. They were surveyed on ocular surface disease index (OSDI), Jankovic rating scale (JRS), blepharospasm disability index (BSDI) prior to injection and 1week, 1month and 3 months after injection. At these time points, closure of the eyelid, tear break up time (BUT), Schirmer test Ｉ, and lower lid tear meniscus height (TMH) were also measured.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
120
Zhongshan Ophthalmic Center, SunYat-senU
Guangzhou, Guangdong, China
RECRUITINGChanges of Jankovic rating scale (JRS) from baseline at 1week, 1month and 3 months
Time frame: 3 months
Changes of lower lid tear meniscus height (TMH) from baseline at 1week, 1month and 3 months
Time frame: 3 months
Changes of blepharospasm disability index (BSDI) from baseline at 1week, 1month and 3 months
Time frame: 3 months
Changes of ocular surface disease index (OSDI) from baseline at 1week, 1month and 3 months
Time frame: 3 months
Changes of tear break up time (BUT) from baseline at 1week, 1month and 3 months
Time frame: 3 months
Changes of closure of the eyelid from baseline at 1week, 1month and 3 months
Time frame: 3 months
Changes of Schirmer test Ｉ from baseline at 1week, 1month and 3 months
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.